Clinical trial · Interventional
Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma
the General Hospital of PLA
NCT03177174CI-TRIAL-00043260completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Drug-Related Side Effects and Adverse Reactions | — | UNRESOLVED | — |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Docetaxel
- interventionNames
- Drug: Docetaxel
- type
- ACTIVE_COMPARATOR
- label
- Cisplatin
- interventionNames
- Drug: Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- DocetaxelCisplatin
- description
- Cisplatin combined with Docetaxel
- interventionNames
- Drug: Cisplatin
- Drug: Docetaxel
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18, \<70 years old, with locally advanced nasopharyngeal carcinoma. Exclusion Criteria: * patients who had accepted radiotherapy before patients with any ather types of cancer
References
Publications (1)
- DERIVEDLuo Y, Cai B, Li B, Liu F, Du L, Zhao D, Fan W, Meng L, Zhang X, Ma L. The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221109974. doi: 10.1177/15330338221109974. PMID 35770295